Molecular Analysis of Liquid-Based Cytological Specimen Using Virtually Positive Sputum with Adenocarcinoma Cells.

EGFR mutation liquid-based cytology lung adenocarcinoma quantitative PCR

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
05 Feb 2020
Historique:
received: 09 01 2020
revised: 29 01 2020
accepted: 03 02 2020
entrez: 9 2 2020
pubmed: 9 2 2020
medline: 9 2 2020
Statut: epublish

Résumé

Liquid-based cytology (LBC) analysis of sputum is a useful diagnostic and prognostic tool for detecting lung cancer. DNA and RNA derived from lung cancer cells can be used for this diagnosis. However, the quality of cytological material is not always adequate for molecular analysis due to the effect of formalin in the commercially available fixation kits. In this study, we examined DNA and RNA extraction methods for LBC analysis with formalin fixation, using lung carcinoma cell lines and sputum. The human non-small cell lung cancer cell lines were fixed with LBC fixation reagents, such as CytoRich red preservative. Quantification of thyroid transcription factor-1 (TTF-1) and actin mRNA, epidermal growth factor receptor (EGFR) DNA in HCC827, H1975, and H1299 cells, and mutation analysis of EGFR in HCC827 and H1975 cells were performed by quantitative PCR (qPCR) and fluorescence resonance energy transfer (FRET)-based preferential homoduplex formation assay (F-PHFA) method, respectively. mRNA and DNA extracted from cell lines using RNA and/or DNA extraction kits for formalin-fixed paraffin-embedded (FFPE) fixed with various LBC solutions were efficiently detected by qPCR. The detection limit of EGFR mutations was at a rate of 5% mutated positive cells in LBC. The detection limit of the EGFR exon 19 deletion in HCC827 was detected in more than 1.5% of the positive cells in sputum. In contrast, the detection limit of the T790M/L858R mutation in H1975 was detected in more than 13% of the positive cells. We also detected EGFR mutations using next generation sequencing (NGS). The detection limit of NGS for EGFR mutation was lower than that of the F-PHFA method. Furthermore, more than 0.1% of positive cells could be cytomorphologically detected. Our results demonstrate that LBC systems are powerful tools for cytopathological and genetic analyses. However, careful attention should be paid to the incidence of false negative results in the genetic analysis of EGFR mutations detected by LBC.

Identifiants

pubmed: 32033355
pii: diagnostics10020084
doi: 10.3390/diagnostics10020084
pmc: PMC7168204
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Cell. 2007 Dec 14;131(6):1190-203
pubmed: 18083107
J Thorac Oncol. 2014 Jan;9(1):33-40
pubmed: 24305007
Thorac Cancer. 2018 Jul;9(7):856-864
pubmed: 29761660
Cancer Cytopathol. 2015 Apr;123(4):258-66
pubmed: 25641902
N Engl J Med. 2002 Aug 15;347(7):472-80
pubmed: 12181401
J Clin Pathol. 2012 Jun;65(6):561-4
pubmed: 22466414
J Cancer Res Clin Oncol. 2014 Jan;140(1):145-150
pubmed: 24281335
Clin Cancer Res. 2015 Jan 15;21(2):484-9
pubmed: 25593345
J Thorac Oncol. 2007 Dec;2(12):1086-90
pubmed: 18090579
Oncotarget. 2017 Nov 20;8(63):106685-106692
pubmed: 29290981
Cancer Cytopathol. 2018 Dec;126(12):1011-1021
pubmed: 30343520
J Clin Pathol. 2012 Jan;65(1):87-91
pubmed: 21945923
Lung Cancer. 2010 Feb;67(2):170-6
pubmed: 19446359
Diagn Cytopathol. 2011 Sep;39(9):703-10
pubmed: 21837660
Acta Cytol. 2004 Nov-Dec;48(6):825-35
pubmed: 15581169
Lung Cancer. 2016 Apr;94:88-95
pubmed: 26973212
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Oncotarget. 2016 Feb 2;7(5):5131-42
pubmed: 26246471
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
pubmed: 15329413
Diagn Cytopathol. 2014 May;42(5):384-90
pubmed: 24167083
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Lung Cancer. 2018 Aug;122:72-75
pubmed: 30032849
BMC Cancer. 2016 Nov 8;16(1):864
pubmed: 27821131
J Proteomics. 2019 Mar 30;196:106-119
pubmed: 30710758
Diagn Cytopathol. 2016 Oct;44(10):833-40
pubmed: 27357064
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
Genes Dev. 2003 Dec 15;17(24):2998-3010
pubmed: 14701871
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Lung Cancer. 2013 Oct;82(1):38-43
pubmed: 23927883
Cancer Cytopathol. 2017 Mar;125(3):178-187
pubmed: 28085233
Clin Transl Med. 2013 Sep 22;2(1):15
pubmed: 24053570
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
Biomed Khim. 2017 May;63(3):181-210
pubmed: 28781253
Int J Cancer. 2010 Dec 15;127(12):2870-8
pubmed: 21351266
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
PLoS Med. 2005 Mar;2(3):e73
pubmed: 15737014
Mod Pathol. 2010 Aug;23(8):1157-64
pubmed: 20526284
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
J Cytol. 2015 Jul-Sep;32(3):159-64
pubmed: 26729975
Asian Pac J Cancer Prev. 2014;15(18):7885-9
pubmed: 25292082
Br J Cancer. 2013 Aug 6;109(3):530-7
pubmed: 23868001
N Engl J Med. 2001 Apr 5;344(14):1031-7
pubmed: 11287972

Auteurs

Takeshi Nishikawa (T)

Department of Diagnostic Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.

Tomomi Fujii (T)

Department of Diagnostic Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.

Shigenobu Tatsumi (S)

Department of Diagnostic Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.

Aya Sugimoto (A)

Department of Diagnostic Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.

Yoko Sekita-Hatakeyama (Y)

Department of Diagnostic Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.

Keiji Shimada (K)

Department of Diagnostic Pathology, Nara City Hospital, Nara 630-8305, Japan.

Masaharu Yamazaki (M)

Department of Central Clinical Laboratory, Nara Medical University Hospital, Nara 634-8521, Japan.

Kinta Hatakeyama (K)

Department of Diagnostic Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.

Chiho Ohbayashi (C)

Department of Diagnostic Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.

Classifications MeSH